Markets:

Overview

News

Currencies

International

Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.610 -0.400 (-19.90%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

6 Analysts Have This to Say About Coherus BioSciences ↗

May 23, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 19, 2023

On Friday, 63 companies hit new 52-week lows.

Via Benzinga

Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 16, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Coherus BioSciences Earnings Preview ↗

May 05, 2023

Via Benzinga

Coherus BioSciences's Return On Capital Employed Overview ↗

March 09, 2023

Via Benzinga

A Preview Of Coherus BioSciences's Earnings ↗

March 03, 2023

Via Benzinga

Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings ↗

May 09, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 09, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

May 09, 2023

We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!

Via InvestorPlace

Looking Into Coherus BioSciences Return On Capital Employed ↗

August 17, 2022

Via Benzinga

Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 09, 2023

Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease.

Via Benzinga

Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business' ↗

May 01, 2023

Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

PVH, First Republic Bank And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗

March 28, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗

February 18, 2023

Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of...

Via Talk Markets

Tesla, NIO And Some Other Big Stocks Moving Lower On Tuesday ↗

December 27, 2022

U.S. stocks traded mixed, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗

December 29, 2022

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.

Via Benzinga

Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket ↗

December 23, 2022

Gainers Expion360 Inc. (NASDAQ: XPON) shares rose 152% to $2.47 in pre-market trading. Expion360 been selected as the exclusive supplier of high-energy lithium ion batteries for an overland trailer...

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Coherus BioSciences Earnings Preview ↗

November 07, 2022

Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Coherus...

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.

Via Benzinga

Coherus's Refiling For Head and Neck Cancer Candidate Accepted By FDA For Review ↗

July 06, 2022

Coherus BioSciences (NASDAQ: CHRS) announced that the United States Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for Toripalimab in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops ↗

May 14, 2022

Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an...

Via Talk Markets

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

Headline News about Coherus Oncology, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today